Lenvatinib: tested with established drugs
43 studies: they are given beside it. Page 1 of 1. Open to participants first (14), then studies with results posted, then the rest; newest registration first within each.
- STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter MethylationNot yet recruitingNCT07754734Phase 2Report a problem
- Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT07691515Phase 3Report a problem
- Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral MelanomaNot yet recruitingNCT07501104Phase 2Report a problem
- Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCCNot yet recruitingNCT07490002Phase 2Report a problem
- STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular CarcinomaRecruitingNCT06880523Phase 2Report a problem
- Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning ModelRecruitingNCT06420440Phase 2Report a problem
- FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver TransplantationNot yet recruitingNCT06409637Phase 1/2Report a problem
- Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract CancerRecruitingNCT06362317Phase 2Report a problem
- Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCCRecruitingNCT06041477Phase 3Report a problem
- Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albuminEnrolling by invitationNCT06030934Phase 2Report a problem
- Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced CholangiocarcinomaRecruitingNCT05823311Phase 3Report a problem
- Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial CarcinomaRecruitingNCT05603910Phase 1Report a problem
- Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced CholangiocarcinomaRecruitingNCT05532059Phase 2Report a problem
- GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced CholangiocarcinomaRecruitingNCT05215665Not applicableReport a problem
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China ExtensionCompletedNCT05523323Phase 3Results postedReport a problem
- Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).TerminatedNCT04949256Phase 3Results postedReport a problem
- Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension StudyCompletedNCT04889118Phase 3Results postedReport a problem
- Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension StudyCompletedNCT04716933Phase 3Results postedReport a problem
- Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension StudyCompletedNCT04676412Phase 3Results postedReport a problem
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)CompletedNCT04199104Phase 3Results postedReport a problem
- A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory OsteosarcomaCompletedNCT04154189Phase 2Results postedReport a problem
- Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)CompletedNCT03898180Phase 3Results postedReport a problem
- Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)CompletedNCT03829332Phase 3Results postedReport a problem
- Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)CompletedNCT03829319Phase 3Results postedReport a problem
- Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)CompletedNCT03820986Phase 3Results postedReport a problem
- Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System TumorsCompletedNCT03245151Phase 1/2Results postedReport a problem
- Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell CarcinomaCompletedNCT03173560Phase 2Results postedReport a problem
- A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid TumorsCompletedNCT02501096Phase 1/2Results postedReport a problem
- Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With OsteosarcomaCompletedNCT02432274Phase 1/2Results postedReport a problem
- A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different TreatmentsCompletedNCT01529112Phase 2Results postedReport a problem
- A Study in Subjects With Recurrent Malignant GliomaCompletedNCT01137604Phase 2Results postedReport a problem
- A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted TreatmentCompletedNCT01136733Phase 1/2Results postedReport a problem
- E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV MelanomaCompletedNCT01133977Phase 1/2Results postedReport a problem
- E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125TerminatedNCT01133756Phase 1/2Results postedReport a problem
- E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC)CompletedNCT00832819Phase 1Results postedReport a problem
- Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural MesotheliomaActive, not recruitingNCT06318286Phase 2Report a problem
- TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular CarcinomaStatus unknownNCT05555316Phase 2Report a problem
- Pembrolizumab and Lenvatinib After Definitive Chemoradiation of Locally Advanced HNSCCActive, not recruitingNCT05433116Phase 2Report a problem
- Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)Status unknownNCT05277675Not applicableReport a problem
- Capecitabine Combined With Lenvatinib and Tislelizumab as Adjuvant Treatment After Resection in Patients With BTCCompletedNCT05254847Phase 2Report a problem
- Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminatedNCT05081180Phase 1Report a problem
- Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular CarcinomaStatus unknownNCT04168944Phase 2/3Report a problem
- Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell CarcinomaCompletedNCT03524326Phase 1Report a problem